April Highlights: National Accolades and Clinical Breakthroughs Supercharge Innovation Momentum at Zhongguancun Life Science Park

Apr 30, 2026 17:30 CST Updated 17:30

WANTAI BioPharm

Biological Diagnostic Reagents and Vaccine R&D, Manufacturer

InnoCare

Innovative Drug Developer

Super Vision

Ophthalmic Disease Treatment Product Developer

BeOne

Developer of Molecular Targeted and Immune Anti-Tumor Drugs

Theia Therapeutics

Biopharmaceutical Manufacturer

Kanova Biopharma

Innovative Immunotherapy Antibody Drug Developer

Insights into International Trends, Understanding the Frontiers

Walking into Zhongguan Village Life Science Park Monthly

Let's take a look at what's new this month.

Recently, the Ministry of Industry and Information Technology released the first batch of science and technology enterprise incubators list, including 402 standard-level and 14 excellence-level incubators. Among them, the Target Innovation Center within the Zhongguan Village Life Science Park was rated as an excellence-level incubator, while the Newborn Nest Innovation Center was rated as a standard-level incubator.

Moreover, the 2025 annual report has begun! All enterprises, individual businesses, and farmers' professional cooperatives registered before December 31, 2025, should submit the 2025 annual report via the National Enterprise Credit Information Publicity System by June 30, 2026, and make it publicly available. The data submitted must be true and complete.

Today's Declaration | The 2025 Annual Report Has Begun

In April, there was a constant stream of good news from the park's enterprises.

In terms of winning awards,WANTAI BioPharmHonored with Eight ESG Authoritative Recognitions, Including the 2025 Outstanding Sustainable Development Practice Case of Listed Companies and the Wind 2025 Top 100 ESG Best Practice of Chinese Listed Companies. Supported by Tsinghua University.InnoCareThe "Beijing Key Laboratory of Intelligent Design and Delivery of Oral Drugs," jointly applied for by the cooperating units, has been successfully approved.

In terms of product development,"Beijing Brain No.1"Entering the GCP clinical validation phase,"Beijing Brain No. 2"Expected to enter clinical validation within 2026.Super VisionObtained Medical Device Manufacturing License.Danxu BiopharmAnnouncement: DXP-106 (IL-1RAP Monoclonal Antibody) Completes First Patient Enrollment in Phase I Clinical Trial in China.BeOne MedicinesAntaix® (Tarlatamab for Injection) Granted Marketing Authorization in China; New Indications for BeOne Medicines' Bahean® and BeOne Medicines' Beizean® Accepted for Marketing Application in China.InnoCarePreclinical data of ICP-B794, a novel antibody-drug conjugate (ADC) targeting B7-H3 developed in China, was presented at the AACR Annual Meeting. Preclinical in vivo efficacy results showed that ICP-B794 demonstrated significantly superior anti-tumor effects compared to other B7-H3 ADCs, with anti-tumor activity observed even at low doses.Theia TherapeuticsPositive Results Achieved in Early Exploratory Clinical Study for Dry AMD Cell Therapy MM001

In terms of the capital market,Portfolio Company of Zhongfa Lingchuang/Life Park Venture Capital FundKanova Biopharma，Announces Completion of a New Round of Financing Worth Hundreds of Millions of RMBThis round of financing was led by Hillhouse Ventures and Beijing Sci-Tech Innovation Fund, with strong support from the Beijing Medical and Health Industry Fund. Jiale Capital and Yuanxi Haihe also participated in the investment.

In addition,Beijing Hetang Shenghua Signs Strategic Cooperation Agreement with Peking University International HospitalIt is reported that this cooperation will give full play to the advantages of each party in cutting-edge clinical medicine, transformation of scientific and technological achievements, and cultivation of the biomedical industry. The collaboration will deepen around key directions such as the joint regional body for clinical research and transformation demonstration of new biomedicine technologies, the Research Center for Longevity and Anti-Aging, and the clinical transformation base of the Innovation Center for Cell and Gene Therapy.

Relevant Review

Headline | Brain-Computer Interface Advances Further! "Beijing Brain No. 1" Enters GCP Clinical Validation Phase

Beijing Daily: "BeiNao II" Expected to Enter Clinical Validation Within 2026

Headline | Super Vision Obtains Medical Device Manufacturing License, World's First Nystagmus Treatment Product Crosses the "Final Hurdle" of Industrialization

Company News | Danxu Biopharmaceutical Announces First Participant Enrolled in Phase I Clinical Trial of DXP-106 (IL-1RAP Monoclonal Antibody) in China

Original Innovation | First Elucidation! Cao Ying/Yang Jing/Chen Jian Team Unveils Key Mechanism of Microglia "Combating" Neurodegenerative Diseases

Corporate News | Beijing Hetao Shenghua Signs Strategic Cooperation Agreement with Peking University International Hospital

First in China! Theia Therapeutics' Cell Therapy MM001 for Dry AMD Shows Positive Results in Early Exploratory Clinical Study

In April, Zhongguan Village Life Science Park carried out a series of industrial activities, including policy briefings for medical device foreign trade enterprises, the Bio-X International Biomedical Industry Competition, intellectual property and financing legal practices for biopharmaceuticals, and an innovation salon on the medical device industry ecosystem, comprehensively supporting high-quality enterprise development.

Relevant Review

Top Prize of 400,000 Yuan! Bio-X International Biomedical Industry Competition Launches Project Recruitment

Headline of the Park | Million-dollar Prize + Full-chain Support! The 9th "Changping Cup" Entrepreneurship Competition of "Entrepreneurial Changping" Kicks Off

Note: The data is sourced from publicly available information. We apologize for any omissions.